These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35366926)

  • 61. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
    Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
    Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
    Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.
    Katz AJ; Kang J
    Front Oncol; 2014; 4():301. PubMed ID: 25389521
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.
    Arscott WT; Chen LN; Wilson N; Bhagat A; Kim JS; Moures RA; Yung TM; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Jul; 9():163. PubMed ID: 25056726
    [TBL] [Abstract][Full Text] [Related]  

  • 66. GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol.
    Pasquier D; Le Deley MC; Tresch E; Cormier L; Duterque M; Nenan S; Lartigau E
    BMJ Open; 2019 Aug; 9(8):e026666. PubMed ID: 31377694
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report.
    Janoray G; Reynaud-Bougnoux A; Ruffier-Loubière A; Bernadou G; Pointreau Y; Calais G
    Cancer Radiother; 2016 Jun; 20(4):275-81. PubMed ID: 27342944
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
    Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
    Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.
    Repka MC; Guleria S; Cyr RA; Yung TM; Koneru H; Chen LN; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch J; Collins SP
    Front Oncol; 2016; 6():122. PubMed ID: 27242962
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15).
    Aghdam N; Pepin A; Buchberger D; Hirshberg J; Lei S; Ayoob M; Danner M; Yung T; Kumar D; Collins BT; Lynch J; Kataria S; Suy S; Collins SP
    Front Oncol; 2020; 10():1060. PubMed ID: 32719744
    [No Abstract]   [Full Text] [Related]  

  • 71. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
    Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
    Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer.
    Gomez CL; Xu X; Qi XS; Wang PC; Kupelian P; Steinberg M; King CR
    Pract Radiat Oncol; 2015; 5(4):257-62. PubMed ID: 25749214
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
    Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes.
    Mazzola R; Figlia V; Rigo M; Cuccia F; Ricchetti F; Giaj-Levra N; Nicosia L; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Alongi F
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2379-2397. PubMed ID: 32372146
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
    Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Salvage Stereotactic Body Radiation Therapy for Local Prostate Cancer Recurrence After Radiation Therapy: A Retrospective Multicenter Study of the GETUG.
    Pasquier D; Martinage G; Janoray G; Rojas DP; Zerini D; Goupy F; De Crevoisier R; Bogart E; Calais G; Toledano A; Chauveinc L; Scher N; Bondiau PY; Hannoun-Levi JM; Silva M; Meyer E; Nickers P; Lacornerie T; Jereczek-Fossa BA; Lartigau E
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):727-734. PubMed ID: 31344433
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
    Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
    Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging.
    Paydar I; Kim BS; Cyr RA; Rashid H; Anjum A; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2015; 5():194. PubMed ID: 26389077
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.
    Katz A; Kang J
    Radiat Oncol; 2014 Jan; 9():1. PubMed ID: 24382205
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.
    Pepin A; Pernia M; Danner MT; Ayoob M; Yung TM; Lei S; Collins BT; Simeng S; Aghdam N; Collins SP
    Cureus; 2021 Mar; 13(3):e13780. PubMed ID: 33842156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.